Sichuan Kelun-Biotech to Present Promising Cancer Drug Results at ASCO 2025

The latest announcement is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that it will present results from six clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These studies include innovative treatments for various cancers, such as non-small-cell lung cancer, triple-negative breast cancer, and nasopharyngeal carcinoma. The results highlight the efficacy of their TROP2 ADC sacituzumab tirumotecan, anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586, with significant outcomes in progression-free survival and objective response rates, potentially enhancing the company’s position in the oncology market.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative drugs. The company specializes in antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), and inhibitors targeting various cancers, with a market focus on oncology treatments.

Average Trading Volume: 700,722

Technical Sentiment Signal: Buy

Current Market Cap: HK$76.36B

For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.